George I. Papakostas, MD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

  • 74Articles
  • 421.5KReads
  • 2003–2025Active
  • 167Collaborators
  • 3.8KCitations

About

George I. Papakostas, MD, is affiliated with the Department of Psychiatry at Massachusetts General Hospital in Boston, Massachusetts. Since 2003, Papakostas has contributed extensively to the fields of depression, psychiatry, neurology, cognition, dementia, metabolic disorders, psychopharmacology, and schizophrenia/schizoaffective disorders. His publications focus on clinical trials and analyses related to major depressive disorder, including studies on esmethadone, esketamine, vortioxetine, and adjunctive treatments, as well as research on treatment-resistant depression and measurement-based care. He has frequently collaborated with Maurizio Fava, Madhukar H. Trivedi, Richard C. Shelton, David Mischoulon, and Jonathan E. Alpert.

Publications

JCP
Commentary

MDD Treatment: Response to Antidepressants

May 19, 2020

Read commentary on inadequate antidepressant response for MDD. Determining where patients are on the response continuum and managing inadequate response.
, , , et al
JCP
Augmentation and Adjunctive Strategies for Inadequate Response in MDD
Educational Activity

Augmentation and Adjunctive Strategies for Inadequate Response in MDD

May 12, 2020

When a patient with major depressive disorder isn't responding to antidepressant treatment, what are your next moves? In this activity, learn from the experts about augmentation and adjunctive strategies.
, , , et al
JCP
Overcoming Challenges to Treat Inadequate Response in MDD
Educational Activity

Overcoming Challenges to Treat Inadequate Response in MDD

May 12, 2020

How do you determine if a patient is experiencing nonresponse to an antidepressant? In this activity, experts discuss augmentation and adjunctive treatment strategies, as well as best practices for...
, , , et al
JCP
Use of Measurement-Based Care to Address Inadequate Antidepressant Response
Educational Activity

Use of Measurement-Based Care to Address Inadequate Antidepressant Response

May 5, 2020

You may think using rating scales to measure depression symptoms takes too long. But that time may be well spent. In this activity, experts discuss the value of measurement-based...
, , , et al
JCP
Recognizing Inadequate Response in Patients With MDD
Educational Activity

Recognizing Inadequate Response in Patients With MDD

May 5, 2020

Can you recognize inadequate antidepressant response? How does it differ from treatment-resistant depression? In this activity, experts discuss definitions of response as well as residual symptoms seen with inadequate...
, , , et al
JCP
Review Article

Maintaining Antidepressant Effects of Ketamine

February 4, 2020

Ketamine infusion can produce rapid antidepressant effects, but how to maintain these initial treatment gains remains unclear. This article suggests directions for future investigation in light of past attempts...
JCP
Original Research

Adjunctive Pimavanserin in Treatment-Resistant MDD

September 24, 2019

The use of atypical antipsychotics as adjunctive treatment for nonresponsive depression is limited by their side effects. This study explores whether pimavanserin can be both an efficacious and tolerable...
, , , et al
JCP
Review Article

Treatment-Resistant Depression Definition and Staging

June 4, 2019

To optimize treatment choices for patients with treatment-resistant depression (TRD), TRD should be defined accurately and unambiguously. This review examines extant descriptions and staging models of TRD and posits...
,
JCP
Original Research

Ziprasidone Augmentation of Escitalopram for Cognition

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
, , , et al
JCP
Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
, , , et al
JCP
Educational Activity

Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change

August 24, 2016

JCP
Meta-Analysis

Monotherapy in Mood Disorders

May 25, 2016

Is one drug good enough? Read this review of 215 double-blind, randomized, placebo-controlled trials to discover which monotherapies have overall short-term efficacy in treating MDD and bipolar depression.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe